materials-logo

Journal Browser

Journal Browser

Advanced Multifunctional Anticancer Nanomaterials

A special issue of Materials (ISSN 1996-1944). This special issue belongs to the section "Biomaterials".

Deadline for manuscript submissions: closed (15 December 2020) | Viewed by 208

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy Texas A & M University, College Station, TX 7743, USA
Interests: nanomedicine; drug delivery system; exosome; theranostics

E-Mail Website
Guest Editor
Department of Biomedical Engineering, Yale University, New Haven, CT 06511, USA
Interests: biomaterials; immunology

Special Issue Information

Dear Colleagues,

As the second leading cause of cancer, there has been a significant demand of new therapeutics to treat this disease. Using biomaterials, including hydrogels, and polymeric nanoparticles, a large extent of investigations have been supplied to satisfy that demand. Usually, these biomaterials encapsulate therapeutic agents, such as anticancer drugs, protein, cytokines, and genes and then subsequently release these agents into the tumor microenvironment, including tumor vessels and tumor tissues. In the case of metal encapsulated biomaterials, they are utilized as a photothermal therapy for cancer treatment. Other advantages of biomaterials for cancer treatment include environmental sensitivity, such as pH, temperature, light, enzyme, which enable them to be smart that can release the encapsulating agents to the specific targeting sites upon the external stimulus.

This Special Issue will present a tight focus on ongoing research in innovative designs for cancer therapy using biomaterials. We invite investigators to contribute original research, as well as review articles, that seek to address these novel ideas. A specific interest will be placed on papers investigating or deliberating new mechanistic ideas that enhance payload encapsulation, improve systemic circulation and tumor targeting specificity, and release payload only in the tumor microenvironment.

Potential topics include, but are not limited to:

  • New synthetic biomaterials for cancer treatment
  • New method of payload encapsulation by biomaterials
  • Investigation of payload release mechanism
  • Enhancement of Biodistribution
  • Biomaterials mediated immunotherapy for cancer
  • Combinatory of cancer treatment by biomaterials

Prof. Dongin Kim
Dr. Jung Seok Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Biomaterials
  • hydrogels
  • nanoparticles
  • cancer therapy

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop